IBI310
As of the edition of 20 October 2026, IBI310 is a drug known only by a code name: in active development; acts on CTLA4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 12, 1 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of IBI310.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | P16410 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 4 | 0 | 0 |
| Phase 2 | 5 | 1 | 1 | 1 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innovent Biologics | Lead sponsor of trials | 2018 to now |
| Innovent Biopharmaceutical Technology | Lead sponsor of trials | 2026 to now |